Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, ...

Bausch Health (BHC) shares rallied 11.7% in the last trading session to close at $8.02. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 23.2% gain over the past four weeks. Bausch stock witnessed a rally after a Bloomberg report said that the company is working with Jefferies Financial Group to explore refinancing some of its debt. The debt refinancing is expected to help the company in the impending spinoff ...

In January, I wrote an article in which I recommended Bausch + Lomb (NYSE: BLCO ) on the grounds that it was trading near its 52-week lows and looked like a good rebound candidate. BLCO stock has I'm Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quincy Institute for Responsible Statecraft. I have ...

CHICAGO, ILLINOIS - MAY 05: Bausch + Lomb eye vitamins are offered for sale at a drug store on May 05, 2022 in Chicago, Illinois. Bausch + Lomb parent company Bausch Health is spinning off the eye-care company with an upcoming IPO which will list on the New York Stock Exchange and TSX with the ticker symbol "BLCO". (Photo by Scott Olson/Getty Images) In May 2022 , Bausch + Lomb (BLCO) was spun off as a separate publicly traded entity, but it continues to be a core part of Bausch Health's business through it ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Bausch Health Companies Inc.'s (BHC) reported second-quarter adjusted earnings per share of 89 cents, on par with the Zacks Consensus Estimate. The reported figure increased from 81 cents in the year-ago quarter due to higher revenues. Total revenues of $2.4 billion were up 11% year over year. The top line also beat the Zacks Consensus Estimate of $2.3 billion. Excluding the impact of foreign exchange of $25 million, acquisitions of $104 million, and divestitures and discontinuations of $14 million, revenue ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-14956 Bausch Health Companies Inc. (Exact name of registrant as specified in its charter) British Columbia , Canada 98-0448205 (State or ot ...

Financial Data and Key Metrics - Q2 2024 revenues for Bausch Health (excluding Bausch + Lomb) were $1.19 billion, up 5% on a reported basis and 6% on an organic basis compared to Q2 2023 [4] - Adjusted EBITDA for Bausch Health (excluding B+L) was $614 million, an 8% increase compared to the prior year [4] - Consolidated revenues for Bausch Health were $2.4 billion, up 11% on a reported basis and 8% on an organic basis over Q2 2023 [15] - Adjusted EBITDA attributable to Bausch Health was $798 million, a 10% increase compared to the same quarter last year [24] - The company ended Q2 with approximately $1.5 billion of liquidity, including $320 million in cash and $950 million available under its revolving credit facility [27] Business Segment Performance - Salix segment revenues increased by $1 million to $558 million, driven by 10% growth in Xifaxan revenue [16] - Xifaxan revenues grew 10% year-over-year, with extended units growing 4% despite flat retail prescription growth [17] - Solta Medical revenues were $102 million, up 16% on a reported basis and 19% on an organic basis, led by strong growth in Asia Pacific [18] - International revenues increased 7% to $276 million, with double-digit organic growth in Canada and mid-single-digit growth in Latin America [18] - Dermatology revenues grew 21% on a reported basis and 25% on an organic basis, benefiting from favorable net pricing comparisons [19] - Neurology revenues grew 11% year-over-year, driven by competitor supply disruptions and favorable net pricing [20] - Generics business revenues declined 11% on a reported basis and 4% on an organic basis due to competitive pressures [21] Market Performance - Asia Pacific markets, particularly South Korea, China, and Taiwan, drove strong growth for Solta, with South Korea nearly doubling its business [4] - Thermage FLX launched in China as a medical device, with early results meeting expectations [10] - The U.S. market for Solta saw a 4% year-over-year decline, but the company is investing in sales teams and tools to drive future growth [19] Strategic Direction and Industry Competition - The company continues to prioritize the full separation of Bausch + Lomb, aiming to ensure both entities are appropriately capitalized [14] - Bausch Health is focused on driving growth through existing assets, targeted investments, and commercial excellence while advancing its R&D pipeline [30] - The company is defending its intellectual property, particularly around Xifaxan, with ongoing litigation against Norwich and Amneal [12][13] - The RED-C program for Rifaximin aims to address a larger market by focusing on preventing hepatic encephalopathy, with top-line results expected by early 2026 [9] Management Commentary on Operating Environment and Future Outlook - Management highlighted the company's fifth consecutive quarter of year-over-year growth in revenue and adjusted EBITDA, positioning it well for the second half of 2024 [4] - The company remains focused on cost management and operational effectiveness while driving growth in key areas such as Xifaxan, Solta, and international markets [30] - Management expressed confidence in the potential of the RED-C program and the aesthetics pipeline, including Thermage FLX and Clear + Brilliant Touch [9][10][11] Other Important Information - The company repaid over $360 million of debt in Q2, including $305 million of bonds with 2025 maturities, and has retired $555 million in principal value of 2025 and 2026 maturities year-to-date [25][26] - Aimee Lenar joined as Executive Vice President of US Pharma, and JJ Charhon will join as CFO in mid-August, bringing extensive industry experience [7] - The company is maintaining its full-year 2024 guidance, expecting revenue of $4.7 billion to $4.85 billion and adjusted EBITDA of $2.36 billion to $2.46 billion [28] Q&A Session Summary Question: Balance sheet and leverage concerns, including potential negotiations with the co-op [32] - The company denied rumors of bankruptcy or insolvency proceedings and reiterated its focus on growing the business and generating results [33] - Management emphasized the strategic priority of separating Bausch + Lomb and ensuring both companies are appropriately capitalized [34][36] Question: Plan B if the separation of Bausch + Lomb is not feasible [39] - The company reiterated that the separation remains a strategic priority and did not provide details on alternative plans [40] Question: Commercial assumptions for the Phase 3 IBD program for Amiselimod [39] - The company believes there is a significant unmet need in the market and is confident in the data supporting the program [40] Question: Xifaxan script dynamics and investment strategy [42] - Management highlighted strong NBRx growth and the potential to treat more patients, particularly in OHE and IBSD [43][45] Question: RED-C trial and its potential impact on the company [49] - The company sees the RED-C program as a significant opportunity to expand the market for Rifaximin, particularly in prevention rather than treatment [51] Question: Solvency and debt maturities [57] - The company highlighted its liquidity position, ability to monetize its BLCO stake, and focus on growing non-Xifaxan businesses like Solta and international markets [62][63] Question: Thermage FLX reception in China and potential IPO for Solta [64] - Management expressed optimism about the growth potential of Solta in China and globally, with no immediate plans for an IPO [65][67]

Bausch Health (BHC) reported $2.4 billion in revenue for the quarter ended June 2024, representing a yearover-year increase of 10.9%. EPS of $0.98 for the same period compares to $0.81 a year ago. The reported revenue represents a surprise of +2.97% over the Zacks Consensus Estimate of $2.33 billion. With the consensus EPS estimate being $0.89, the EPS surprise was +10.11%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

Bausch Health (BHC) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.81 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.11%. A quarter ago, it was expected that this drugmaker would post earnings of $0.75 per share when it actually produced earnings of $0.59, delivering a surprise of -21.33%. Over the last four quarters, the compan ...